Incyclix Bio has raised an additional $5 million in Series B financing to support its treatment for advanced and resistant cancers. The cell cycle control company raised the funds from new investor Hatteras Venture Partners, which will help advance Incyclix Bio’s lead compound INX-315. The compound is a novel, potent and selective CDK2 inhibitor for the treatment of advanced […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!